£10.5m contract win, trading update for the period ended 31 March 2020, and the potential impact of COVID-19

IXICO plc (AIM: IXI) is pleased to announce today the signing of a substantial new contract for a late-phase open label study in Huntington’s disease (HD).  The four-year contract runs to 2024 with a total value of £10.5 million with the expectation that the majority of the revenue will be generated in 2022 and 2023.  This brings the total value of the new contracts signed to-date in the current financial year to £15 million.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH